Atlas Trials

Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

Clinical trial NCT02033941 · TERMINATED

Trial details

NCT number
NCT02033941
Sponsor
Hillel Grossman
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Alzheimer's Disease
Start date
2018-07-03
Primary completion
2019-10-04
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.